

Bod Science last patient completes Phase IIB Clinical Trial of Schedule 3 CBD product for Australian market

- 'Last patient, last visit' milestone reached with all patients completing Phase IIB Can-Rest Insomnia trial
- Bod's Phase IIB clinical trial is the only advanced Schedule 3 Cannabidiol (CBD) product candidate for the Australian market
- Topline clinical trial results expected late August 2023
- Dossier submission expected in the final quarter of the calendar year

Sydney, Australia – 10 July 2023: Cannabis focused drug development and product innovation company Bod Science Limited ("Bod" or "the Company") (ASX: BOD) is pleased to provide a landmark update on their phase IIB clinical trial for a new Schedule 3 Cannabidiol (CBD) product for the Australian market being undertaken by Australia's leading sleep research organisation, the Woolcock Institute of Medical Research.

Bod is delighted to announce that all patients have now completed the Phase IIB Clinical Trial – officially completing the final step in R&D for their new product. Bod's unique CBD formulation is presented in a unique soft gel format and utilises a patent protected encapsulation technology that improves the bioavailability of the CBD extract. The completed clinical trial is the only advanced Schedule 3 (Pharmacist Only) CBD product candidate for the Australian market.

The trial has assessed the efficacy of a uniquely developed Schedule 3 CBD formulation on symptoms associated with insomnia in 198 participants over an 8-week period. Schedule 3 products can be sold to Australian consumers over-the-counter without a prescription.

Bod expects to release top-line results in late August 2023. Once the results are reported, Bod intends to submit the dossier to the TGA for their review of what is anticipated to be the first Schedule 3 CBD product to be made available in Australia.

Management commentary:

CEO Ms Jo Patterson said: *"We're thrilled to have reached this important milestone in delivering our uniquely developed Schedule 3 CBD formulation. The now completed clinical trial is the only advanced Schedule 3 CBD product candidate for the Australian market."*

"A huge thank you to all our patients for volunteering to be part of the trial. Thanks also to our hardworking research partners at the Woolcock Institute of Medical Research. We look forward to receiving the results of the study next month."

This announcement has been approved by the Board of Bod Science Limited.

-ENDS-

About Bod Science:

Bod Science (ASX:BOD) is a cannabis focused drug development and product innovation company.

Bod is focused on progressing research and development with a defined clinical trial pathway to commercialise and deliver premium, scientifically proven and trusted products for patients and consumers.

The company has a number of existing partnerships with large corporate companies and collaborations with leading research organisations to advance the use of Cannabis related medicines with therapeutic indications.

For more information please contact:

Jo Patterson
Chief Executive Officer
Info@bodaustralia.com
+61 2 9199 5018

Amalie Schreurs
White Noise Communications
amalie@whitenoisecomms.com
+61 431 636 033